Abstract-Skeletal muscle and myocardium express NOS I, an elongated splice variant of neuronal-type nitric oxide (NO) synthase (NOS I), and NOS III, endothelial-type NO synthase, respectively. This study was designed to elucidate whether vascular smooth muscle also contains a constitutively expressed NO synthase isoform. In the rat, NOS I contains an insert of 102 nucleotides after nucleotide 2865 of the cDNA, yielding a protein of 164 kd. Reverse transcription-polymerase chain reaction with primers flanking this insert and with insert-specific primers indicated that endothelium-denuded rat aorta expresses both brain-type NOS I and NOS I. RNase protection analyses with an antisense RNA probe overlapping the NOS I insert detected significant amounts of NOS I mRNA and lesser amounts of NOS I mRNA in endothelium-denuded aorta. Western blots using a specific polyclonal antibody recognizing NOS I and NOS I showed a major band of the 160-kd NOS I and a lesser band of a slightly larger protein in endothelium-denuded aorta. Immunohistochemistry demonstrated low levels of NOS I/NOS I immunoreactivity in the medial layer of rat aorta, whereas the endothelium expressed only NOS III immunoreactivity. When the adventitia also was removed, NOS I and NOS I mRNA decreased markedly but remained detectable in the medial layer. In functional experiments with endothelium-denuded rat aortic rings (that contained no NOS III), contractions induced by KCl were markedly increased in the presence of the NOS inhibitor N G -nitro-L-arginine. These data demonstrate that 2 subforms of NOS I are expressed in nonendothelial components of rat aorta: NOS I and lesser amounts of NOS I. Under certain conditions, this NOS I/NOS I expression could serve as a backup system to the functionally predominant NOS III.
N itric oxide (NO) is a gaseous molecule with important biological functions in the cardiovascular system and elsewhere. It is produced by 3 isoforms of NO synthase (NOS), namely, neuronal-type NOS I, inducible-type NOS II, and endothelial-type NOS III (for review see Reference 1) . NOS I and NOS III are usually expressed constitutively. NOS II is not normally found in resting cells and tissues (with the exception of skeletal muscle and intestine 2 ) but can be induced in many cell types by bacterial lipopolysaccharide (LPS) and cytokines.
In skeletal muscle, all 3 isoforms of NOS have been described. NOS I is localized at the sarcolemma and especially enriched at the neuromuscular end plate. [2] [3] [4] In the rat, skeletal muscle expresses an alternatively spliced form of NOS I, namely, NOS I, that contains a 102-nucleotide (nt)/34 -amino acid insert after nucleotide 2865 of the NOS I cDNA. 5 NOS II has been found to be constitutively expressed in type I fibers of guinea pig skeletal muscle. 2 The expression could be further increased with LPS. 2 Immunohistochemical evidence indicating the presence of NOS III in rat skeletal muscle has also been published. 6 This isoform has been localized mainly to mitochondria. 6 Skeletal muscle-derived NO is likely to participate in the regulation of contractile function. 2, 3 Cardiac myocytes, another type of muscle cells, have been reported to express NOS III constitutively. 7 This isoform seems to mediate the muscarinic cholinergic attenuation of contractile responsiveness to ␤-adrenergic agonists. 7 However, the same study failed to detect NOS I in ventricular myocytes. 7 NOS II has been shown to be induced in cardiac myocytes by cytokines. 8, 9 Recently, NOS I immunoreactivity has been described in the media of the carotid artery of both normotensive and spontaneously hypertensive rats. 10 In hypertensive rats, NO produced by this enzyme negatively modulated the contractions induced by angiotensin II. 10 Exposure of cultured human aortic smooth muscle cells to fluid flow has been shown to result in an increased NO production. 11 Western blots demonstrated that the only isoform expressed by these cells was NOS I. 11 Another study using Western blot analysis showed a low expression of NOS III protein in endotheliumdenuded rat aorta. 12 This expression increased when animals were treated with monocrotaline to induce heart failure. 12 NOS II is not normally present in vascular smooth muscle cells but can be induced by cytokines or LPS. 13, 14 These somewhat controversial findings prompted us to investigate whether vascular smooth muscle and adventitia of an intact artery, namely, rat aorta, express a NOS isoform constitutively, to identify the isoform(s), and to test the possible functional significance of this expression for the modulation of vascular tone. We demonstrate that NOS III expression is clearly restricted to the endothelium. The nonendothelial components of rat aorta show a clearly detectable expression of NOS IϾNOS I. Functional studies with endothelium-denuded rat aortic rings indicate that this enzyme can modulate vascular contractility under conditions in which intracellular calcium levels are elevated (eg, after KCl depolarization).
Materials and Methods

Preparation of Rat Aortas and Control Tissues
Female Sprague-Dawley rats (200 to 300 g) were killed by a blow to the head and exsanguination. The thorax was immediately opened, and a large segment of the aorta (thoracic and abdominal) was placed in ice-cold PBS. The aorta was dissected free of fat and connective tissue and opened longitudinally. Depending on the experiment performed, the artery was left intact, or the endothelium with or without the adventitia was removed mechanically. As positive controls of tissues expressing NOS I and NOS I, respectively, the cerebellum and the gastrocnemius muscle were removed from the rats as well. For RNA and protein isolation, the tissues were rapidly frozen in liquid nitrogen. For immunohistochemistry, aortas were frozen in 2-methylbutane at Ϫ80°C.
RNA Isolation and RT-PCR
Total RNA was isolated from aorta (intact, endothelium-denuded, or medial layer alone), rat cerebellum, and gastrocnemius muscle by acid guanidinium thiocyanate/phenol/chloroform extraction. 15 RNA (2 g) was annealed with 40 ng random hexamer primers and reverse-transcribed with SuperScript reverse transcriptase according to the manufacturer's instructions. Reverse transcription (RT)-generated cDNAs encoding for rat NOS I, NOS I, and ␥-actin were amplified by polymerase chain reaction (PCR) as described previously (40 cycles). 16 The primer pairs specific for NOS I, NOS I, and ␥-actin were selected by analysis of the published cDNA sequences (Table) . 5, 17, 18 PCR products were separated on 1.8% agarose gels in Tris borate/EDTA buffer containing 0.5 g/mL ethidium bromide.
Cloning of Rat NOS I/NOS I and ␥-Actin cDNA Fragments
The amplified cDNA fragments (NOS I, 380 base pairs [bp]; ␥-actin, 353 bp) were cloned into the EcoRV site of vector pCR-Script with a SureClone Ligation Kit, generating the cDNA clones pCR-NOS I-rat and pCR-␥-actin-rat. NOS I and ␥-actin cDNAs were sequenced by use of the dideoxy-mediated chain termination method ( T7 Sequencing Kit, Pharmacia).
Preparation of Antisense RNA Probes and RNase Protection Analyses
To generate radiolabeled antisense RNA probes for RNase protection analyses, the cDNA clones pCR-NOS I-rat and pCR-␥-actin-rat were linearized with EcoRI and AspI, respectively, extracted with phenol/chloroform, and concentrated by ethanol precipitation. These DNAs (0.5 g) were in vitro-transcribed for 60 minutes at 37°C by using T3/T7 RNA polymerase and [␣-32 P]UTP. Then, the template DNA was degraded with DNase I (RNase free, 10 U/L) for 45 minutes at 37°C, and the labeled RNA was precipitated with ethanol.
RNase protection analyses were performed with the above [␣-
32 P]UTP-labeled probes as described. 19 Briefly, after a denaturation step for 10 minutes at 85°C, 20 g of total RNA (isolated as described above) was hybridized for 14 hours at 51°C with a 200 000 cpm-labeled NOS I/NOS I cRNA probe (435 nt) and a 30 000 cpm-labeled ␥-actin cRNA probe (183 nt) in hybridization buffer (40 mol/L PIPES [pH 6.7] , 400 mmol/L NaCl, 1 mmol/L EDTA, and 50% formamide). Then, the hybridization mixture was incubated for 30 minutes at 30°C with 300 L digestion buffer (10 mmol/L Tris HCl [pH 7.4], 300 mmol/L NaCl, and 5 mmol/L EDTA) containing 3.5 g RNase A and 25 U RNase T1. The reaction was stopped by addition of 70 L of a buffer (10 mmol/L Tris HCl [pH 7.8], 5 mmol/L EDTA, and 2.85% SDS) containing 70 g proteinase K.
After incubation for 15 minutes at 37°C and phenol/chloroform extraction, the samples were concentrated by ethanol precipitation and analyzed by electrophoresis using 6% polyacrylamide/8 mol/L urea gels. Gels were dried and exposed to x-ray films for Ϸ3 days. Densitometric analyses were performed using the PhosphoImager system (Bio-Rad). The protected RNA fragments for NOS I, NOS I, and ␥-actin were 302, 377, and 110 nt, respectively.
Western Blotting
For Western blotting, the aorta (intact, endothelium-denuded, or medial layer alone), cerebellum, and gastrocnemius muscle were homogenized on ice. Combined soluble and CHAPS-solubilized particulate fractions (100 g each) were separated on 5% or 7.5% SDS-polyacrylamide gels and electroblotted to nitrocellulose membranes (Schleicher & Schuell). 20, 21 Blots were blocked for 60 minutes at room temperature in Tris-buffered saline (TBS, consisting of 10 mmol/L Tris HCl [pH 7.4] and 154 mmol/L NaCl) containing 5% (wt/vol) nonfat dry milk and 0.05% (wt/vol) Tween 20. They were then incubated overnight at 4°C with rabbit polyclonal antibodies to NOS I (1:2000) 22 or NOS II (1:1000) 23 or a mouse monoclonal antibody to NOS III (1:500) in PBS containing 1% (wt/vol) bovine serum albumin and 0.1% (wt/vol) Tween 20. After 3 washes with TBS containing 5% (wt/vol) nonfat dry milk and 0.05% (wt/vol) Tween 20, the blots were incubated for 60 minutes at room temperature with a goat anti-rabbit or a horse anti-mouse alkaline phosphatase-conjugated secondary antibody. After 3 washes with TBS containing 0.05% (wt/vol) Tween 20, bands were visualized with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium chloride. 
Oligonucleotide Primers Used for Amplification of NOS I, NOS I, and ␥-Actin cDNAs
Immunohistochemistry
To detect NOS I in rat aorta, serial sections of 10 m were made with a cryostat (Leica). The sections were fixed for 5 minutes in 4% (wt/vol) paraformaldehyde at 4°C. Immunohistochemistry was performed as described previously. 16 Briefly, after blocking of endogenous peroxidase and biotin, sections were washed for 10 minutes in antibody incubation medium (4% [wt/vol] nonfat dry milk and 0.3% [vol/vol] Triton X-100 in PBS). They were then incubated for 30 minutes in a 1:10 dilution of normal serum from the species in which the secondary antibody was generated (goat or horse). Sections were incubated overnight at 4°C with one of the following primary antibodies: a rabbit polyclonal antibody to NOS I (1:500) and a mouse monoclonal antibody to NOS III (1:100). Sections were washed in incubation medium and then incubated for 60 minutes with the secondary biotinylated antibody (1:100, a goat anti-rabbit IgG or a horse anti-mouse IgG). After several washes in PBS, cells were exposed for 20 minutes to an avidin DH-biotinylated horseradish peroxidase H complex (1:100 in PBS, Vectastain Elite ABC Kit). The chromogen reaction was performed with 3,3Ј-diaminobenzidine (DAB peroxidase substrate tablet set). Cells were washed in distilled water, mounted in glycerol gelatin, and coverslipped. In control experiments, the primary antibodies were replaced with rabbit preimmune serum or mouse IgG.
Measurement of Vascular Responses
Rat aortic segments were obtained as described above. 25 .0, and glucose 10.6. The solution was aerated continuously with 95% O 2 and 5% CO 2 . The pH was 7.4. Isometric tension of the aortic rings was recorded with force transducers coupled to DC amplifiers and a pen recorder. The initial load on the tissues was adjusted to 1 g. Before the actual experiment, preparations were allowed to stabilize for Ϸ1 hour. Rings were precontracted several times with 0.1 mol/L norepinephrine (NE) until the contractile response was reproducible. The absence of endothelium was verified by a complete loss of relaxation to acetylcholine (1 mol/L). Then, concentration-response curves were generated with either KCl (5 to 90 mmol/L) or NE (0.1 nmol/L to 1 mol/L). When the KCl concentration was increased, the appropriate amounts of NaCl were omitted to maintain osmolarity. After a washout period, rings were incubated for 30 minutes with 300 mol/L N G -nitro-L-arginine (L-NNA). Then, a second concentrationresponse curve was generated with KCl and NE in the presence of the NOS inhibitor.
Data Analysis
Data represent meanϮSEM. Statistical differences were determined by factorial ANOVA followed by the Fisher protected least significant difference test for comparison of multiple means.
Materials
The DAB peroxidase substrate tablet set, goat anti-rabbit antibody conjugated to alkaline phosphatase, horse anti-mouse antibody conjugated to alkaline phosphatase, mouse immunoglobulin G, LPS from Escherichia coli (serotype 055:B5), L-NNA, and (Ϫ)-norepinephrine bitartrate salt were obtained from Sigma Chemical. SuperScript reverse transcriptase was from Life Technologies. EcoRI, EcoRV, random hexamer primer, the SureClone Ligation Kit, Taq DNA polymerase, Taq polymerase reaction buffer, and the T7 Sequencing Kit were from Pharmacia. pCR-Script was from Stratagene. AspI, DNase I, RNase A, RNase T1, proteinase K, and T3 RNA polymerase were from Boehringer-Mannheim. [␣-32 P]UTP was from ICN. Biotinylated goat anti-rabbit IgG, biotinylated horse anti-mouse IgG, goat normal serum, horse normal serum, and the Vectastain Elite ABC Kit were from Vector Laboratories. Mouse monoclonal antibody to NOS III was from Transduction Laboratories.
Results
Detection of NOS I and NOS I mRNA in Rat Aorta
For the detection of NOS I and NOS I mRNA in rat aorta, 2 different RT-PCR approaches were used. In a first set of experiments, primers flanking the NOS I insert were used (Figure 1 ). With RNA from rat cerebellum, this yielded a 340-bp NOS I fragment, whereas with RNA from rat gastrocnemius muscle, only a 442-bp NOS I fragment was amplified (Figure 1 ). RNA from intact aorta or endotheliumdenuded rat aorta or from the medial layer of the aorta showed the 340-bp fragment (Figure 1) .
In a second approach, the same antisense primer was used but was combined with a sense primer specific for the NOS RT-PCR using primers (NOS I-5Ј and NOS I-3Ј) flanking the NOS I insert, thereby amplifying NOS I and/or NOS I mRNA. Total RNA was isolated from intact aorta (Aorta), endothelium-denuded aorta (Aorta-Endo), or the medial layer alone (Aorta-Endo-Adv). RNAs from cerebellum (Cereb) and gastrocnemius muscle (Gastrocn) were used as positive controls for brain-type NOS I and skeletal muscle-type NOS I, respectively. The RNAs were reverse-transcribed, and the cDNAs were used as template in the subsequent PCR. The expected DNA fragments were 340 bp for NOS I and 442 bp for NOS I. The gel is representative of 5 experiments with similar results.
I insert (Figure 2 ). This yielded a 380-bp fragment in gastrocnemius muscle (Figure 2 ). This fragment was amplified to a lesser extent from RNAs from cerebellum and aorta (intact, endothelium-denuded, or medial layer alone; Figure  2 ). The amplified 380-bp cDNA fragment from endotheliumdenuded rat aorta was cloned into the EcoRV site of vector pCR-Script. Its sequence was found to be 100% identical to the sequence reported for rat skeletal muscle, 5 thereby demonstrating that NOS mRNA is expressed in the endothelium-denuded aorta.
An antisense RNA probe generated from this NOS-specific sequence was used in subsequent RNase protection analyses. Because this probe overlaps the NOS insert, it recognizes both NOS I and NOS I mRNAs. As expected, RNA from gastrocnemius muscle showed mainly the 377-nt fragment for NOS I (95.3Ϯ3.7% of total, nϭ5; Figure 3 ). RNA from cerebellum produced predominantly the 302-nt fragment of brain-type NOS I, but contained 9.6Ϯ1.9% NOS I mRNA (nϭ5, Figure 3) . Also, the endothelium-denuded aorta contained brain-type NOS I and NOS I mRNA with brain-type NOS I representing 92.1Ϯ2.8% of total (nϭ5). In the medial layer alone, the overall amount of both NOS I subforms was less than in total aorta, but the relative amounts of NOS I and NOS I remained about the same (with NOS I representing 8.7Ϯ1.5% of total, nϭ5; Figure 3 ).
Detection of NOS Protein in Rat Aorta
Western blots (from 5% SDS-polyacrylamide gels) using a specific polyclonal antibody to NOS I and NOS I demonstrated the 160-kd NOS I protein in the combined soluble and CHAPS-solubilized particulate fractions of the cerebellum, the endothelium-denuded aorta, and the medial layer alone ( Figure 4A) . A slightly larger protein (probably NOS I) was found in gastrocnemius muscle. This larger protein was also seen in cerebellum, endothelium-denuded aorta, and the medial layer alone ( Figure 4A ). On 7.5% SDS-polyacrylamide gels, the 2 protein bands could not be distinguished (nϭ3, data not shown). Endothelium-intact and endotheliumdenuded aortas did not differ in their NOS I/NOS I content (nϭ3, data not shown). Homogenates from total aorta showed a 135-kd NOS III band with the anti-NOS III antibody ( Figure 4B ). This band disappeared when the endothelium or the endothelium plus adventitia was removed ( Figure 4B ). Western blots using a polyclonal anti-NOS II antibody demonstrated the 130-kd NOS II protein in LPS-induced aortas but not in normal aortas (nϭ4, data not shown).
Immunohistochemistry
To determine the cellular location of the NOS isoforms in rat aorta, sections were first stained with a polyclonal antibody recognizing NOS I and NOS I. NOS I/NOS I immunoreactivity was found in the smooth muscle layer of the aorta ( Figure  5A ). NOS I/NOS I immunoreactive material was also detected in the adventitia ( Figure 5B ). The endothelium showed no NOS I/NOS I immunoreactivity ( Figure 5A ). Immunoreactivity was lost when the anti-NOS I antibody was replaced with preimmune serum ( Figure 5D and 5E). Staining with a monoclonal antibody to NOS III was clearly restricted to the endothelium ( Figure 5C) ; Figure 5F shows a negative control.
Functional Significance of NOS I/NOS I in Rat Aorta for Regulation of Vascular Tone
When endothelium-denuded aortic rings were constricted with increasing concentrations of KCl (5 to 90 mmol/L), the addition of the NOS inhibitor L-NNA (300 mol/L) produced a marked increase in the contractile response ( Figure  6A ). In contrast, when tension was induced with NE (0.1 nmol/L Figure 3 . RNase protection analysis of RNAs from endotheliumdenuded aorta (Aorta-Endo) and from the medial layer (AortaEndo-Adv) using an antisense RNA probe hybridizing to both NOS I and NOS I, yielding protected fragments of 302 and 377 nt, respectively. A ␥-actin probe was used for standardization (protected fragment, 110 nt). Again, RNAs from cerebellum (Cereb) and gastrocnemius (Gastrocn) served as positive controls for NOS I and NOS I, respectively. T indicates tRNA; M, molecular size marker; and P, combined undigested ()NOS I and ␥-actin probes. The gel is representative of 5 independent experiments with similar results. Western blot analysis of combined soluble and CHAPSsolubilized particulate fractions from different tissues. A, Protein samples from cerebellum (Cereb), gastrocnemius muscle (Gastrocn), endothelium-denuded aorta (Aorta-Endo), and the medial layer (Aorta-Endo-Adv) were separated on 5% polyacrylamide gels and electroblotted to nitrocellulose membranes. A polyclonal antibody recognizing both NOS I and NOS I was used for detection. This gel is representative of 3 experiments with similar results. B, Protein samples from intact aorta (Aorta), from aorta without endothelium (Aorta-Endo), and from the medial layer alone (Aorta-EndoAdv) were separated on 7.5% polyacrylamide gels. A monoclonal antibody to NOS III was used for detection. This gel is representative of 4 experiments with similar results.
to 1 mol/L), the maximum contraction remained unchanged in the presence of 300 mol/L L-NNA ( Figure 6B ). Only at low concentrations of NE was a small increase in the contractile response detectable with the NOS inhibitor ( Figure 6B ).
Discussion
The present study demonstrates that nonendothelial components of rat aorta express 2 subforms of NOS I: the brain-type enzyme and the skeletal muscle-type NOS I, the former being the predominant form. The overall expression levels of NOS I/NOS I in endothelium-denuded aortas are low, and only part of this NOS I/NOS I is found in the smooth muscle layer. The remainder is likely to reside in nitrergic neurons within the adventitia.
Controversial information has been published concerning the presence of NOS in vascular smooth muscle. Recently, it has been shown by Western blot that the smooth muscle layer of rat aorta expresses Ϸ22% of NOS III protein of the total aorta. 12 This expression increased when rats were treated with monocrotaline to induce heart failure. 12 On the other hand, Western blots of protein from cultured human aortic smooth muscle cells demonstrated a specific NOS I signal but showed no immunoreactivity for NOS II and NOS III. 11 While the present study was under review, another study appeared demonstrating NOS I protein in the media of the rat carotid artery. 10 Our Western blot and immunohistochemistry data (Figures 4 and 5) clearly indicate that NOS III is expressed only in the endothelium and not in the medial layer of rat aorta. On the other hand, Western blots and staining of aortic sections with our anti-NOS I antibody showed specific immunoreactivity in only the smooth muscle layer and not in the endothelium of rat aorta. Therefore, our results agree with the data involving NOS I expression in cultured human aortic smooth muscle cells and carotid arteries. 10, 11 NOS I is subject to alternative splicing. 1 In the rat, an additional 102-bp insert between exons 16 and 17 corresponds to an alternatively spliced isoform in skeletal muscle, referred to as NOS I. 5 A NOS I-specific antibody detected the resulting 164-kd protein in differentiated skeletal muscle and heart. 5 NOS I has been reported to have the same activity as brain-type NOS I. 5 Another group cloned the same NOS I cDNA from rat penile corpora cavernosa. 24 This subform was expressed alone in rat penis, urethra, prostate, and skeletal muscle and was coexpressed with brain-type NOS I in the pelvic plexus, bladder, and cerebellum.
Therefore, we decided to investigate whether rat vascular smooth muscle, the third muscle cell type besides skeletal muscle and heart, also expresses NOS I alone or together with brain-type NOS I. We compared NOS I/NOS I RNA and protein expression in rat aorta with that of cerebellum (positive control for brain-type NOS I) and with gastrocnemius muscle (positive control for NOS I). Preliminary studies with rat aorta and cultured endothelial cells have clearly indicated that NOS I/NOS expression is absent from endothelial cells. Two different RT-PCR approaches and RNase protection analyses have clearly demonstrated that NOS I mRNA is expressed as a minor form together with brain-type NOS I in the adventitia and the medial layer of the rat aorta (Figures 1 to 3) . PCR is nonquantitative by definition. If 2 competing templates are present in different amounts, it is not unusual that only one dominant band is amplified. In Figures 1 and 2 , this is shown for cerebellum and aorta. Therefore, only RNase protection analyses have been used for quantification (see Figure 3) . Additional evidence for the expression of NOS I came from the sequencing of a NOS I fragment cloned from deendothelialized rat aorta. Interestingly, the NOS I/NOS I ratio in the aortic wall is similar to that in cerebellum, which also expresses NOS I as a minor splice variant (Figures 1 to 3) .
Western blot analyses of gastrocnemius muscle showed a protein that was slightly larger than the 160-kd NOS I protein in cerebellum (Figure 4 ). The small difference in molecular weight became apparent only when the proteins were separated on 5% SDS-polyacrylamide gels. It seems likely that the larger protein is NOS I. The larger protein band was also detected in rat cerebellum, where, however, the 160-kd protein prevailed. The endothelium-denuded aorta also expressed the 160-kd NOS I protein together with the slightly larger protein. Removal of the adventitia resulted in a reduction of brain-type NOS I expression, whereas the larger protein remained largely unimpaired.
To demonstrate a potential functional significance of NOS I/NOS I in the regulation of vascular tone, endotheliumdenuded rat aortic rings were constricted with the physiological vasoconstrictor NE. Blocking NOS activity with L-NNA produced only a small increase in tension at lower NE concentrations. NE is known to induce only a transient increase in free intracellular calcium levels in smooth muscle as well as phosphorylation of myosin light chain. 25, 26 However, free intracellular calcium levels rapidly return to basal or even below basal levels while tone is maintained (for review see Reference 27) Therefore, the calcium-regulated NOS I is probably inactive again at the time when a stable tension plateau is reached. Consequently, in a second approach, we induced tension with the membrane-depolarizing agent KCl. Under these conditions, free intracellular calcium levels stay elevated for a longer period of time, and L-NNA produces a marked increase in contraction. This suggests that under these conditions, NOS I/NOS I is active and negatively contributes to the tension reached. Thus, under conditions of elevated free calcium levels in vascular smooth muscle (eg, in hypertension), the NOS I/NOS I system, in addition to the predominant endothelial NOS III, may be relevant in controlling vascular tone.
We conclude from our data that 2 subforms of NOS I are expressed in nonendothelial structures of rat aorta: the braintype NOS I and the skeletal muscle-type NOS I, with NOS I being the predominant form. Their distribution in the vascular wall differs from that of skeletal muscle (where NOS I prevails) and resembles that of the cerebellum (which expresses mainly the NOS I). NOS I/NOS I may serve as a backup system to the predominant endothelial NOS III in certain pathophysiological conditions.
